|
|
Volumn 33, Issue 3, 2001, Pages 2258-2262
|
|
Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AZATHIOPRINE;
CORTICOSTEROID;
IMMUNOSUPPRESSIVE AGENT;
OKT 3;
TACROLIMUS;
ADOLESCENT;
ADULT;
AGED;
ARTICLE;
BLOOD;
CLINICAL TRIAL;
COMPARATIVE STUDY;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG COMBINATION;
ETHNIC GROUP;
FEMALE;
GRAFT REJECTION;
GRAFT SURVIVAL;
HUMAN;
IMMUNOLOGY;
LIVER TRANSPLANTATION;
MALE;
MIDDLE AGED;
MORTALITY;
MULTICENTER STUDY;
PATHOLOGY;
PATIENT SELECTION;
PHYSIOLOGY;
RANDOMIZED CONTROLLED TRIAL;
REOPERATION;
SAFETY;
SURVIVAL RATE;
TREATMENT OUTCOME;
ADOLESCENT;
ADRENAL CORTEX HORMONES;
ADULT;
AGED;
AZATHIOPRINE;
DRUG THERAPY, COMBINATION;
ETHNIC GROUPS;
FEMALE;
GRAFT REJECTION;
GRAFT SURVIVAL;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
LIVER TRANSPLANTATION;
MALE;
MIDDLE AGED;
MUROMONAB-CD3;
PATIENT SELECTION;
REOPERATION;
SAFETY;
SURVIVAL RATE;
TACROLIMUS;
TREATMENT OUTCOME;
|
|
EID: 18044404792
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/S0041-1345(01)01983-2 Document Type: Article |
|
Times cited : (4)
|
|
References (8)
|
